Aptiv Solutions Awarded Pivotal International Cancer Vaccine Trial

RESTON, Va.--(BUSINESS WIRE)--Aptiv Solutions, a leader in designing and executing adaptive clinical trials, announced it has been selected to manage a major breast cancer clinical vaccine program for Galena Biopharma, a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena’s key product is NeuVax™, a cancer immunotherapy aimed at treating targeted breast cancer patient populations.

MORE ON THIS TOPIC